Study: Cannabis-Based Treatments Linked to Long-Term Improvements in Migraine Symptoms and Quality of Life
- The study from Imperial College London and King’s College London found that cannabis-based medicinal products (CBMPs) lead to sustained improvements in migraine symptoms, anxiety, sleep quality, and overall quality of life over a two-year period based on patient-reported outcomes.
- Data from 203 adults in the UK Medical Cannabis Registry, all of whom had not found relief from conventional migraine treatments, showed significant improvements in headache impact, anxiety, sleep, and well-being using measures like HIT-6, MIDAS, and anxiety scores.
- At two years, 54% of patients had clinically meaningful improvement in headache impact, 67% reported better overall quality of life, and higher THC doses correlated with greater migraine-related disability improvement, though dosing variability limits firm conclusions.
- Safety data revealed 15.3% of participants experienced mostly mild or moderate adverse events, with some severe cases reported; researchers note the study’s observational nature cannot prove causation and call for randomized controlled trials to confirm efficacy and safety.
A study published in Brain and Behavior by researchers from Imperial College London and King’s College London found that cannabis-based medicinal products (CBMPs) are associated with sustained improvements in migraine symptoms, anxiety, sleep quality, and overall quality of life, based on patient-reported outcomes tracked for up to two years.
The research analyzed data from 203 adults enrolled in the UK Medical Cannabis Registry who were prescribed CBMPs for migraine after failing to find relief from conventional treatments. Patients were evaluated using standardized measures including the Headache Impact Test (HIT-6), Migraine Disability Assessment (MIDAS), anxiety scores, sleep quality, and overall health-related quality of life.
Across multiple timepoints, patients experienced statistically significant improvements in headache impact, anxiety levels, sleep, and general well-being. These benefits were observed consistently for up to 24 months, although migraine-specific disability scores showed the strongest improvements within the first year before leveling off.
At the two-year mark, 54% of patients achieved a clinically meaningful improvement in headache impact, while 67% reported better overall quality of life. Anxiety and sleep scores also improved across all measured intervals.
The study also found that higher THC doses were associated with a greater likelihood of improvement in migraine-related disability, though researchers caution that variability in dosing and patient response limits firm conclusions.
In terms of safety, 15.3% of participants reported adverse events, the majority of which were mild or moderate. However, some severe effects were recorded, including rare cases of confusion and delirium.
Researchers emphasize that while the findings are encouraging, the study’s observational design means it cannot establish causation. They conclude that randomized controlled trials are needed to confirm whether cannabis-based treatments directly reduce migraine symptoms and to better understand optimal dosing and safety.